MARKET

TRIL

TRIL

TRILLIUM THERAPE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.87
-0.23
-2.84%
Pre Market: 7.84 -0.03 -0.38% 08:00 07/06 EDT
OPEN
8.10
PREV CLOSE
8.10
HIGH
8.28
LOW
7.78
VOLUME
893.23K
TURNOVER
--
52 WEEK HIGH
9.66
52 WEEK LOW
0.2405
MARKET CAP
656.65M
P/E (TTM)
-4.7769
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TRIL stock price target is 11.32 with a high estimate of 15.08 and a low estimate of 8.85.

EPS

TRIL News

More
Hedge Funds Have Never Been This Bullish On Trillium Therapeutics Inc. (TRIL)
Insider Monkey · 06/15 12:42
Top Biotech Stocks for Q3 2020
Investopedia · 06/09 19:09
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 95 companies set new 52-week highs.
Benzinga · 06/02 14:33
Cancer Summit Presses Toward Treatments in Covids Shadow
Bloomberg · 06/01 11:02
72 Biggest Movers From Friday
Gainers Adaptimmune Therapeutics plc (NASDAQ: ADAP) shares jumped 127.8% to close at $11.07 on Friday after the company announced updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology Annual Meeting.
Benzinga · 06/01 08:53
Trillium Therapeutics (TRIL) Investor Presentation - Slideshow
Seeking Alpha - Article · 05/29 21:24
Why Trillium Therapeutics Is Trading Higher Today
Benzinga · 05/29 15:52
Why Trillium Therapeutics Is Trading Higher Today
Trillium Therapeutics (NASDAQ: TRIL) shares are trading higher on Friday, after the company provided an update on TTI-622 at ASCO. The company said dosing has progressed through the first five cohorts up to 4 mg/kg dose level and showed a "strong safety p
Benzinga · 05/29 14:52

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About TRIL

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
More

Webull offers kinds of Trillium Therapeutics Inc stock information, including NASDAQ:TRIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRIL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRIL stock methods without spending real money on the virtual paper trading platform.